Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection

International Journal of STD and AIDS

Volumn 22, Issue 3, 2011, Pages 146-150

  Chamberland, A ^a,e   Sylla, M ^a,e   Boulassel, M R ^b   Baril, J G ^c   Cote P ^a,c   Thomas, R ^d   Trottier, B ^a,d   Rouleau, D ^a,e   Routy, J P ^b   Tremblay, C ^a,e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Clinique Medicale du Quartier Latin   (Canada)

^d Clinique Medicale l'Actuel   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Acute infection; Primary HIV 1; Sequence diversity; Treatment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRAL GENETICS; VIRUS REPLICATION;

ACUTE DISEASE; ADULT; ANTI-RETROVIRAL AGENTS; EVOLUTION, MOLECULAR; FEMALE; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 79955382045     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2010.010292     Document Type: Article

References (35)

1. Diaz RS, Sabino EC, Mayer A, et al. Lack of dual HIV infection in a transfusion recipient exposed to two seropositive blood components. AIDS Res Hum Retroviruses 1996;12:1291-5
2. Zhang LQ, MacKenzie P, Cleland A, et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993;67:3345-56
3. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261:1179-81
4. McNearney T, Hornickova Z, Markham R, et al. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci USA 1992;89:10247-51
5. Goodenow M, Huet T, Saurin W, et al. HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr 1989;2:344-52
6. Iwami S, Nakaoka S, Takeuchi Y. Viral diversity limits immune diversity in asymptomatic phase of HIV infection. Theor Popul Biol 2008;73:332-41
7. Nowak MA. Evolutionary Dynamics. New York: Harvard University Press, 2006
8. Nowak MA, Anderson RM, McLean AR, et al. Antigenic diversity thresholds and the development of AIDS. Science 1991;254:963-9
9. Nowak MA, May RM. Mathematical biology of HIV infections: antigenic variation and diversity threshold. Math Biosci 1991;106:1-21
10. Starcich BR, Hahn BH, Shaw GM et al,. Identification and characterization of conserved and variable regions in the envelope gene of HTLV III/LAV, the retrovirus of AIDS. Cell 1986;45: 637-48
11. Riddle TM, Shire NJ, Sherman MS, et al. Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infection. J Virol 2006;80:10591-9
12. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73:10489-502
13. Herbeck JT, Nickle DC, Learn GH, et al. Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol 2006;80:1637-44
14. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004;303:2019-22
15. Sagar M, Wu X, Lee S, Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006;80:9586-98
16. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003;422:307-12
17. Routy JP, Machouf N, Edwardes MD, et al. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS 2004;18:2305-12
18. Ndongala ML, Peretz Y, Boulet S, et al. HIV Gag p24 specific responses secreting IFN-gamma and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load. Clin Immunol 2009;131:277-87
19. Hu QX, Barry AP, Wang ZX, et al. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J Virol 2000;74:11858-72
20. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-80
21. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007:24:1596-9
22. Bagnarelli P, Mazzola F, Menzo S, Montroni M, Butini L, Clementi M. Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. J Virol 1999;73:3764-77
23. Delwart EL, Pan H, Sheppard HW, et al. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 1997;71:7498-508
24. Ganeshan S, Dickover RE, Korber BT, et al. Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol 1997;71:663-77
25. Greenier JL, Van Rompay KK, Montefiori D, et al. Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. Virol J 2005;2:11
26. Masciotra S, Owen SM, Rudolph D, et al. Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS 2002;16:1887-98
27. Draenert R, Allen TM, Liu Y, et al. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med 2006;203:529-39
28. Jones NA, Wei X, Flower DR, et al. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 2004;200:1243-56
29. Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1infection among injection drug users. J Virol 2010;84:6241-7
30. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105:7552-7
31. Li H, Bar KJ, Wang S, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010;6:e1000890
32. Bello G, Casado C, Garcia S, et al. Plasma RNA viral load is not associated with intrapatient quasispecies heterogeneity in HIV-1 infection. Arch Virol 2004;149:1761-71
33. Mani I, Gilbert P, Sankale JL, et al. Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/ G-IbNG infection. J Virol 2002;76:10745-55
34. Cheng-Mayer C, Brown A, Harouse J, et al. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 1999;73: 5294-300
35. Chackerian B, Rudensey LM, Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 1997;71:7719-27